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background: Every year 30% of individuals above age 65 fall, and falls are the principal cause of bone fractures. To reduce fracture
incidence requires both prevention of falls and maintenance of bone strength.
methods: PubMed searches were performed, for studies of the epidemiology of fractures, bone physiology, endocrine effects, osteo-
porosis measurement, genetics, prevention and effectiveness. Topic summaries were presented to the Workshop Group and omissions
or disagreements were resolved by discussion.
results: Ageing reduces bone strength in post-menopausal women because estrogen deﬁciency causes accelerated bone resorption.
Bone mineral density (BMD) decreased more than 2.5 standard deviation below the mean of healthy young adults deﬁnes osteoporosis,
a condition associated with an increased risk of fractures. Risk factors such as age and previous fracture are combined with BMD for a
more accurate prediction of fracture risk. The most widely used assessment tool is FRAXTM which combines clinical risk factors and
femoral neck BMD. General preventive measures include physical exercise to reduce the risk of falling and vitamin D to facilitate calcium
absorption. Pharmacological interventions consist mainly in the administration of inhibitors of bone resorption. Randomized controlled
trials show treatment improves BMD, and may reduce the relative fracture risk by about 50% for vertebral, 20–25% for non-vertebral
and up to 40% for hip fractures although the absolute risk reductions are much lower.
conclusions: Although diagnosis of osteoporosis is an important step, the threshold for treatment to prevent fractures depends on
additional clinical risk factors. None of the presently available treatment options provide complete fracture prevention.
Key words: falls / bone fractures / osteoporosis / ageing / bone mineral density
Introduction
Fractures in major bones occur more often in later life and are associ-
ated with considerable morbidity and mortality (Johnell and Kanis,
2006; Compston et al., 2009). Fractures in fragile bones are associated
with osteoporosis, a skeletal disease characterized by low bone mass
and impaired bone structure, leading to bone fragility and increased
fracture risk (Sambrook and Cooper, 2006). The most frequent
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osteoporotic fractures are those of the vertebrae, lower forearm and
hip. Vertebral fractures are not always clinically evident, but fractures
of the lower forearm and hip are painful with loss of limb function and
fractures of the hip require hospitalization (Kanis et al., 2008a). The
ultimate cause of limb fractures is usually a fall and falling is more
common in the elderly, which means that any strategy to prevent frac-
tures must address not only bone strength but also the tendency to fall
(Petridou et al., 2008).
The ﬁrst step in prevention protocols is the diagnosis of osteoporo-
sis by measurement of bone mineral density (BMD); when osteoporo-
sis is present, whether treatment is indicated depends on the level of
fracture risk, which varies with age and other factors. Treatment
options for women, at least prior to the Women’s Health Initiative
(WHI) study, included hormone treatment (HT). The WHI study con-
ﬁrmed that, even in women who were not at high risk, estrogen alone
or with progestin signiﬁcantly reduced fracture rates (Cauley et al.,
2003; Anderson et al., 2004). The effect was small, however,
because women aged 50–60 years who were most likely to use HT
have a low risk of fracture. In addition, cardiovascular and cancer
adverse events were more numerous than the hip fractures prevented.
HT of menopause is no longer recommended for fracture preven-
tion and the majority of osteoporosis treatments now involve drugs
with speciﬁc effects on bone. As a result, clinicians not in the ﬁeld
of reproductive medicine, rather than gynecologists are involved in
this treatment. Nevertheless, women coming to gynecology and
menopause clinics remain concerned about osteoporosis and its
risks. The purpose of this review, therefore, is to provide their clini-
cians with information to guide patients in their choices. The review
covers the burden of illness, bone physiology and treatment strategies.
Methods
Searches were done in Medline and other databases by individual partici-
pants in the Workshop about epidemiology of falls and fractures, bone
physiology, endocrine effects on bone physiology, genetics of bone
strength, osteoporosis measurement, non-pharmaceutical and pharma-
ceutical prevention and their effectiveness. Selection criteria were (i)
highest quality studies: prospective cohort studies for diagnosis and prog-
nosis, and randomized controlled trials (RCTs) for prevention and treat-
ment; and (2) studies most relevant to clinical practice involving female
patients. Each subject summary was presented to the Workshop Group
where omissions or disagreements were resolved by discussion.
Frequency of falls
Falling, not osteoporosis, is the strongest single risk factor for fractures
in elderly individuals. Although a one standard deviation (1 SD)
reduction in BMD increases the fracture risk by up to 2.5 times, a side-
ways fall increases the risk of hip fracture by three to ﬁve times
(Ja¨rvinen et al., 2008).
A fall is ‘an unexpected event in which the participant comes to rest
on the ground, ﬂoor or lower level’ (Lamb et al., 2005). When a
person falls, the type and severity of the fall is likely to determine
whether a fracture occurs. The type of fall is deﬁned by the direction
and the associated energy. The severity of a fall reﬂects the distance
fallen or the height from which the fall occurs.
In a community of 409 people aged 65 years, each year 30% had a
fall, and older women (above age 80) had a 30% increased risk of
falling as compared with older men (O’Loughlin et al., 1993). Many
falls are non-injurious, but one in ﬁve falls among senior citizens may
require medical attention and about 1 in 20 falls result in a fracture;
these rates are doubled above the age 75 years (Kannus et al., 2005).
Falls cause a large burden of disease and disability among senior citi-
zens and are costly to health services. Half of the deaths due to injury
in older people in the European Union (EU) are a consequence of a
fall, resulting in about 40 000 deaths each year (Petridou et al.,
2008). In the year 2000 the total cost of unintentional falls in older
people in the UK was estimated to be about £1 billion (GBP)
(Scuffham et al., 2003).
Mortality rates from falls differ widely within the EU, with a 10-fold
variation between the highest rates observed in Hungary and the
Czech Republic, and the lowest rates in Bulgaria, Spain and Greece
(Petridou et al., 2008). Mortality rates from falls among the elderly
in most European countries have declined from the early 1990s to
the early 2000s, although increases in rates have been noted in a
few countries, such as Finland, Ireland and Latvia (Petridou et al.,
2008). Some of the differences in rates may reﬂect different certiﬁca-
tion practices between countries.
Prevalence of fractures
In the year 2000 the number of clinically evident fractures in women
worldwide was estimated to be 5.5 million, of which 1.1 million
were at the hip, 1.3 at the forearm, 0.9 at the spine, 0.5 at the
humerus and 1.9 at other sites. For total fractures and for hip frac-
tures, the peak age was between 75 and 79 years (Johnell and
Kanis, 2006).
The estimated prevalence of osteoporotic fractures worldwide in
women above age 50 years was around 35 million, of which
13.9 million were in Europe, 9.0 million in the Western Paciﬁc,
6.4 million in the Americas, 4.5 million in Southeast Asia, 0.8 million
in the Eastern Mediterranean and 0.2 million in Africa (Johnell and
Kanis, 2006).
At age 50 years the lifetime absolute risk of hip fractures in women
was 7% in a study from Australia, 15% in a study from the USA and
ranged between 11 and 30% in ﬁve studies from Europe (Ahmed
et al., 2009). Lifetime risk of osteoporotic fractures lies within the
range of 40–50% in women and 13–22% in men (Johnell and Kanis,
2005).
Adult bone remodeling
Bones have a complex anatomy (Fig. 1) and provide structural support
for muscle attachments and act as a reservoir for the storage of
calcium and phosphate in the regulation of mineral homeostasis.
The process of bone remodeling is responsible for renewal and
repair of the skeleton during adult life (Fig. 2). Bone remodeling
starts with attraction of osteoclast precursors to the target site, prob-
ably by local release of chemotactic factors from areas of microdam-
age. The osteoclast precursors then differentiate into mature
osteoclasts and attach to the bone surface by forming a sealing
zone. The osteoclasts then secrete hydrochloric acid and proteolytic
enzymes including cathepsin K into the space underneath the sealing
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zone. In the process of bone resorption the acid dissolves the mineral
and the cathepsin K degrades bone collagen. When resorption is com-
plete, osteoclasts undergo programmed cell death and bone formation
begins with the attraction of osteoblast precursors to the resorption
site. The osteoblast precursors differentiate into mature osteoblasts
which deposit new bone matrix in the resorption lacuna, until the
hole is ﬁlled. Some osteoblasts become trapped in bone matrix and
differentiate into osteocytes. Osteocytes act as biomechanical
sensors and produce several molecules that inﬂuence bone remodel-
ing and phosphate metabolism including sclerostin (SOST), ﬁbroblast
growth factor 23 (FGF23) and dentin matrix acidic phosphoprotein
1 (Dmp1) (Bonewald and Johnson, 2008).
In normal individuals, bone mass increases during skeletal growth to
reach a peak at the beginning of the third decade and at this point
bone resorption and formation are equally balanced. Levels of peak
bone mass are strongly inﬂuenced by genetic factors although diet
and exercise also play a role (Ralston and de Crombrugghe, 2006).
After the age of about 45 bone mass falls, particularly in women
due to an accelerated phase of bone loss which occurs as the result
of estrogen deﬁciency at the menopause. The estrogen deﬁciency
causes imbalance between bone resorption and bone formation,
such that the amount of bone removed during the remodeling cycle
slightly exceeds that which is replaced. With increasing age there is
a reduction in bone turnover from that observed immediately after
the menopause, although values remain higher than in premenopausal
women. With advancing age there is also a tendency for fat cells (adi-
pocytes) to accumulate in the bone marrow and this is thought to be
due to an age-related reduction in the ability of bone marrow stromal
cells to differentiate into osteoblasts and an increase in their ability to
differentiate into fat cells. It is of interest that rosiglitazone and related
compounds promote adipocyte differentiation at the expense of
osteoblast differentiation and predispose to osteoporosis through
this mechanism (Lazarenko et al., 2007).
Several circulating hormones including parathyroid hormone (PTH),
estrogen and 1,25-dihydroxyvitamin D, regulate bone remodeling.
These hormones have direct effects on bone cells but also act by reg-
ulating local production of mediators in the bone micro-environment
such as cytokines and growth factors, which then regulate bone cell
activity.
The most important mediators of osteoclast activity are receptor
activator of nuclear factor kappa B (RANK), RANK ligand (RANKL)
and Osteoprotegerin (OPG) (Hofbauer et al., 2000). Bone resorption
is stimulated by RANKL, which binds to RANK and causes osteoclast
activation by up-regulating nuclear factor kappa B (NFkB) and other
signaling pathways. This process is blocked by osteoprotegerin
which acts as a ‘decoy’ receptor for RANKL (Fig. 3). It is already avail-
able one new pharmaceutical, denosumab, is a human monoclonal
antibody to the RANKL that blocks its binding to RANK, thus inhibit-
ing the development and activity of osteoclasts and thereby decreasing
bone resorption (Cummings et al., 2009).
Bone formation is regulated by many factors including PTH, bone
morphogenic proteins (BMP) and molecules in the Wnt signaling
pathway. PTH promotes osteoblast differentiation and stimulates pro-
liferation of osteoblast precursors, whereas BMP promote differen-
tiation of osteoblast precursors to form mature osteoblasts. There
are at least 19 members of the Wnt family and in particular Wnt7b
and Wnt10b play a role in regulating bone formation (Krishnan
et al., 2006) by activating lipoprotein receptor-related protein 5
(LRP5) which together with Frizzled forms a receptor for Wnt family
members. Binding of Wnt causes activation of the LRP5 pathway
which stimulates bone formation by increasing levels of beta-catenin
within the osteoblast (Johnson et al., 2004). Activation of LRP5 signal-
ing in osteoblasts also inhibits bone resorption by increasing pro-
duction of osteoprotegerin (Glass et al., 2005). A variety of
inhibitors of LRP5 signaling have also been identiﬁed, including
soluble Frizzled-Related Proteins (sFRP), Dickkopf (Dkk) and SOST
and it is likely that regulation of bone formation depends on the
balance between levels of the stimulatory Wnt molecules and levels
of the inhibitors such as sFRP and SOST. Sclerostin is of particular
interest since it is produced by osteocytes in response to mechanical
loading and probably acts as a mediator of the effects of mechanical
Figure 1 Bone anatomy and microanatomy.
Figure 2 The bone remodeling cycle.
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loading on the skeleton (Robling et al., 2008). Recent research has also
shown that various other pathways play a role in regulating bone mass
and bone turnover including the sympathetic nervous system through
production of catecholamines (Takeda et al., 2002), serotonin, acting on
the 5-hydroxytryptamine (serotonin) receptor 1 b (Htrb1) receptor
which is expressed on osteoblasts (Yadav et al., 2008) and by canna-
binoids, acting through the type 1 (CB1) and type 2 (CB2) receptors
(Idris et al., 2005; Ofek et al., 2006; Idris et al., 2009) and by nitric
oxide which regulates the effects of proinﬂammatory cytokines and
estrogens on the skeleton (Van’t hof et al., 2000; Armour et al., 2001).
Thus, there are several determinants of bone remodeling (Table I)
and the process is regulated through a variety of pathways (Table II),
which provide multiple therapeutic targets for the prevention and
treatment of bone disease.
Ovarian hormones and bone
metabolism
As suggested in the 1940s by Albright and Reifenstein, ovarian hor-
mones play a pivotal role on bone development and homeostasis.
The consequences of natural reduction in sexual steroid hormone
levels cause decreased mineralization and increased bone resorption.
In men and women, estrogens play the most important role in this
change, as evidenced by the remarkable effects of estrogen therapy
in post-menopausal women, which reduces bone resorption and
decreases the fracture rate (Cauley et al., 2003). Although some
evidence suggests that androgens can inﬂuence bone expansion,
studies in knockout mice as well as the description of women and
men with abnormal estrogen metabolism, such as CYP 19 aromatase
deﬁciency, androgen insensitivity and low estrogen production, indi-
cate that estradiol is the key regulator of bone growth and mainten-
ance (Syed and Khosla, 2005). Estrogens indeed control the balance
between osteoblasts the bone matrix forming cells and bone-
resorbing osteoclasts. Further, recent ﬁndings suggest that locally pro-
duced estrogens may contribute to the turnover and function of bone
tissues independently of systemic estrogens (Li et al., 2009).
Figure 3 Key regulators of osteoblast and osteoclast function. Great proportion of the RANKL is present in a free form and is produced by different
types of cells.
........................................................................................
Table I Key determinants of peak bone mass and bone
loss.
Peak bone mass Bone loss
Genetics (70–80%) Sex hormone deﬁciency
Body weight Body Weight
Sex hormones Genetics
Diet Diet
Exercise Immobility
Diseases
Drugs (among others): Corticosteroids,
Aromatase inhibitors, Glitazones
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Estrogens act mainly through nuclear ligand activated–receptors,
essentially estrogen receptor ERa and also ERb which bind to speciﬁc
response elements on the promoters of speciﬁc genes. Interestingly,
30% of estrogen regulated genes do not have estrogen response
elements and this suggests they are activated by indirect mechanisms
through other transcription factors.
Non-genomic effects of estrogens have been well described; these
very rapid mechanisms are mediated by membrane receptors, and
activation of kinases which modulate intracellular calcium and cAMP
levels, and/or activation of MAP kinases and inositol phosphate-3
kinase pathways.
ERa and ERb are expressed in a pleiotropic manner, and in particu-
lar in the bone and cartilage (Venken et al., 2008; Tanko et al., 2008).
Their expression has been characterized in osteoblasts, osteoclasts,
osteocytes, chondrocytes, as well as in bone medulla. ERa is mostly
present in cortical bone and is mainly involved in bone differentiation.
Estrogens affect precursors of osteoblasts and osteoclasts which
increase their number following castration in mice. Osteoclast differ-
entiation involves the activation of several transcription factors such
as M-CSF, RANKL and osteoprotegerin. All these factors are modu-
lated by estrogens. In addition osteoblast apoptosis is inhibited by
estrogens.
Finally, estrogens regulate formation, activity and half life of osteo-
clasts. This effect explains the increase in bone resorption observed
after menopause. In this context, interleukin-1 (IL-1), tumor necrosis
factor a (TNFa) and interleukin-6 (IL-6), play an important role in the
bone loss following menopause, since their production by osteoblasts
is inhibited by estrogens.
These complex mechanisms through which estrogens regulate bone
resorption and formation, are of paramount importance in health care
as evidenced by the remarkable effects of estrogen therapy in women
with inactive ovaries. In addition, the application of selective estrogen
receptor modulators (SERMs) to the treatment of osteoporosis, has
also been a crucial lead in our clinical armamentarium since SERMs
can also decrease the risk of breast cancer, a classical limitation for
the use of estrogens in aging women (Kung et al., 2009).
ERa remains the key mediator of estrogen effects in bone, although
the role of ERb in this tissue remains to be elucidated. As a conse-
quence, ERb speciﬁc ligands do not prevent or treat osteoporosis.
Progress is expected both to dissociate the bone effect of estrogens
from their uterotrophic consequences and their effects on breast pro-
liferation. The co-administration of SERMs and estrogen seems to be
of great interest. Also, the characterization of all the molecular steps of
estrogen action through transcription factors, and kinases, may help to
ﬁnd new therapeutic targets.
Relationship between BMD and
fracture risk
Osteoporosis is deﬁned as a systemic skeletal disease characterized by
low bone mass and micro-architectural deterioration of bone tissue,
with a consequent increase in bone fragility and susceptibility to frac-
ture risk. BMD, along with bone geometry, micro-structure and bone
turnover are the determinants of bone strength (Seeman and Delmas,
2006a). The diagnosis of osteoporosis is based on the determination
of areal BMD at the spine or proximal femur. Areal BMD accounts for
two-thirds of the variance of the strength of isolated bone specimens.
Besides bone mineral mass- and bone turnover-related variables, clini-
cal risk factors can capture features of osteoporotic fracture risk above
those provided by BMD and/or bone remodeling rate. No single
symptom or sign can conﬁrm or rule out osteoporosis. However, clini-
cal features may have cumulative effects, and may be combined to
provide a signiﬁcant and meaningful estimate of fracture risk which
can be used in a treatment decision strategy and in the deﬁnition of
an intervention threshold (Kanis et al., 2008a).
Femoral neck BMD appears to be a better predictor of fracture of
the proximal femur, based on long-term prospective longitudinal
studies with fracture as the outcome. Since femoral neck BMD is
less inﬂuenced by osteoarthritis than spine BMD, it represents the
most suitable measure for the diagnosis of osteoporosis in the
elderly (Marshall et al., 1996). Indeed, above the age of 65, spine
can barely be considered for diagnostic purposes. Femoral neck
BMD is the variable included in the WHO-FRAXw tool (Kanis
et al., 2007). Measuring several skeletal sites (spine, neck and total
hip) may increase the prevalence of subjects with osteoporosis, but
it does not improve the accuracy of fracture prediction.
AWorld Health Organization panel (1994) has proposed that BMD
falling more than 2.5 SD below the mean values in healthy young
adults is the diagnostic criterion for osteoporosis (T-Score). Its
measure is made as follows: T-Score ¼ (measured BMD 2 Young
Adult BMD)/Young Adult SD. Ninety-ﬁve percent of the populations
are included in +2 SD and 99% in +3 SD (Fig. 4). The fracture rate
in the reference population of healthy young adults is very low. This
approach to diagnosis is similar to the measurement of blood pressure
for the diagnosis of hypertension. The T-score is a diagnosis threshold,
which should clearly be distinguished from a therapeutic threshold. For
the latter, other factors such as age, concomitant clinical risk factors,
bone turnover and the beneﬁts, side effects and cost of treatment
should be considered as well (Kanis et al., 2007).
Table II General and local regulators of bone turnover.
General factors Mechanical
Exercise
Bed rest
Neurogenic
Leptin/adrenergic
Nitric oxide
Cannabinoids
Hormonal
Calcitonin
Sex hormones
PTH/1,25 vitamin D
Thyroxine, TSH, GH/IGF
Corticosteroids
Local factors Osteoclasts
RANK, RANKL, OPG
IL-1, TNF, IL6, TGFb
Nitric oxide, Cannabinoids
Osteoblasts
Wnt/LRP-5/SOST
TGFb/BMP
Nitric oxide
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The prevalence of subjects with bone mass values below the 2.5 SD
threshold increases with age, reaching 40% at the age of 80. The life-
time risk of any skeletal fracture in a 50-year-old woman depends on
the incidence of fracture in the relevant population and on her life
expectancy. For instance, in Switzerland, which has a prolonged life
expectancy, lifetime risk of fracture is as high as 51.3% for a woman
at the age of 50. For a man, due to the different bone diameter,
this risk is 20% (Lippuner et al., 2009). However, it should be remem-
bered that there is no BMD threshold value for the risk of osteoporo-
tic fracture, only that the relationship is characterized by a continuous
increasing gradient of risk with the decrease of BMD.
Identiﬁcation of women at risk
In white populations about 50% of women and 20% of men aged over
50 will have a fragility fracture in their remaining lifetime (Sambrook
and Cooper, 2006). The consequences for the individual and the
cost to the health service of fragility fractures are serious. A range
of preventive treatments exists but as all treatments have some
risks, side effects or drawbacks, it is important to select the people
who most need treatment by identifying those at greatest risk of
fracture.
The risk factors for fracture include: previous osteoporotic fracture
(or a fracture associated with a low-trauma event) family history of hip
fracture, having a fall and of course osteoporosis itself. Although there
is long list of well-recognized risk factors for osteoporosis (Table III),
ostoporosis is not the most important of the risk factors for fracture
(Waugh et al., 2009).
Previous fracture
In a meta-analysis involving almost 45 000 women from 11 inter-
national cohorts followed for a total of 250 000 women-years, a
history of previous low-impact/osteoporotic fracture almost
doubled the risk of osteoporotic fracture (RR 1.86; CI 1.75–1.98)
compared with women without a history of fracture (Kanis et al.,
2004). Impressively almost one in ﬁve women (19.2%) who develop
a vertebral fracture (the commonest osteoporotic fracture) will have
another fracture within 1 year (Lindsay et al., 2001). The effect on
risk of a previous fracture may not be conﬁned to low-impact frac-
tures; in a study of women over 65, a previous high-trauma fracture
was associated with 34% greater risk of subsequent fracture compared
with women with no previous fracture (Mackey et al., 2007).
Falls
Falls are associated with an increased risk of fracture, independently of
osteoporosis. In a cohort study of over 40 000 older people in care
homes falls increased the risk of hip fracture by 30% (Stolee et al.,
2009).
Osteoporosis
The lifetime risk of fracture at age 50 is 50% for any woman (Kanis
et al., 2007) and the risk of fracture almost doubles for each SD
reduction in BMD (Johnell et al., 2005). In the 1990s the measurement
of BMD by Dual Energy X-ray Absorptiometry (DEXA) became the
gold standard for assessing fracture risk. Other investigations are avail-
able for bone mass measurement, like quantitative ultrasound or
quantitative computer tomography. Low ultrasounds-determined stiff-
ness, which combines speed of sounds and broad band attenuation,
predicts fracture risk similarly to DEXA-based BMD measurement.
Biochemical markers evaluate bone turnover. However, BMD
remains the major criterion used for diagnosing osteoporosis.
Although BMD is a simple, quick, non-invasive and now relatively
cheap investigation, many fractures occur in people who do not
have a low BMD. Since not everyone who has osteoporosis will
have a fracture, in most settings guidelines, based on known risk
factors for osteoporosis, are used to decide who is eligible for BMD
measurement.
Risk factors for osteoporosis
Non-modiﬁable risk factors include sex, age, family history and early
menopause (Waugh et al., 2009) (Table III). Women have a lower
total bone mass, they live longer compared with men and are,
especially after the menopause, at increased risk of losing bone.
Depending on lifestyle, men lose 0.0–0.9% of bone annually,
women 0.9–1.2%. Age is a second non-modiﬁable risk factor: osteo-
porosis in Caucasian American women is 27% between 50 and 59,
32% between 60 and 69 and 41% over 70. Women with an early
menopause should be considered at higher risk than women of the
same age with late menopause. A family history (parents, sibs) of
osteoporosis (‘easily fracturing’) contributes signiﬁcantly to an
Figure 4 Changes in bone density T-score with age. T-score ¼
(young adult BMD 2 measured BMD)/young adult SD. Osteopenia
T-score between 1 and 2.5 SD. Osteoporosis T-score below 2.5
SD. Pink line, females; blue line, males.
........................................................................................
Table III Risk factors for osteoporosis (Waugh et al.,
2009).
Not modiﬁable Modiﬁable
Increasing age Weight
Female sex Smoking
Caucasian ethnicity Alcohol
Age at menopause Exercise
Family History Diet
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individual’s risk (Soroko et al., 1994). Individual BMD decreases as the
number of family members with osteoporosis increases. Modiﬁable
risk factors include lack of exercise, low body weight, inadequate
diet, excess alcohol use and smoking (Law and Hackshaw, 1997;
Waugh et al., 2009).
BMD guidelines
A host of recommendations for who should have BMD screening for
osteoporosis have been produced by a variety of professional organ-
izations (Lim et al., 2009). In general, most guideline recommendations
are based on age and sex with or without known clinical risk factors.
The guidelines in the USA and Canada recommend screening all
women aged 65 and older and all men aged 70 and older regardless
of the presence of risk factors and also recommend screening of all
post-menopausal women who have known risk factors. The more
recent guidelines recommend using an osteoporosis screening tool.
A number of these have been developed, the diagnostic accuracy of
the best known tools was assessed among 7779 USA women aged
67 years. The osteoporosis self-assessment tool (OST) (0.2×
weight in kg minus age) had the greatest area under the receiver oper-
ating characteristic curve (AUC 0.76, 95% CI 0.74, 0.77). By itself,
however, weight had an AUC of 0.73 (95% CI 0.72, 0.75), which
was better than the values for other scores, age alone or prior fracture
(Gourlay et al., 2008).
Fracture prediction
Assessment of BMD captures only part of the fracture risk and lacks
sufﬁcient sensitivity for population screening; moreover other risk
factors, particularly age, add important information about fracture
risk (Fig. 5). Various attempts have been made to construct assess-
ment tools which use clinical risk factors with or without BMD to
predict fracture risk and thereby to set thresholds for preventive
therapy (Lim et al., 2009). The most widely used of these tools is
FRAXTM which combines easily obtained clinical risk factors (body
mass index, prior history of fracture, parental history of hip fracture,
use of steroids, rheumatoid arthritis and other secondary causes of
osteoporosis, current smoking and alcohol intake) with femoral neck
BMD (Kanis et al., 2008b). FRAXTM is internet based and can be
adapted for use in different countries with varying prevalence of osteo-
porosis and fracture.
Genetic determinants of
osteoporosis
A genetic contribution to the pathogenesis of osteoporosis, account-
ing for 50–80% of the inter-individual variability in bone mass and
quality, has been demonstrated in twin and family studies (Torgerson
et al., 1996; Gennari et al., 2002). Personal and family history predicts
fractures in early post-menopausal women, an effect that decreases
with age but does not disappear (Michae¨lsson et al., 2005). Genetic
factors contribute to osteoporosis by inﬂuencing not only BMD, but
also bone size, bone quality and bone turnover (Peacock et al., 2002).
Given the complex biology of the skeleton, it is likely that bone
mass is under the control of a large number of genes, many of
which exert only minor effects on BMD, whereas a few may contrib-
ute substantially to variability in this trait. Among the numerous genes
implicated in the etiopathogenesis of skeletal disorders such as osteo-
porosis, the most likely candidate genes are: those encoding for bone
matrix protein synthesis, calciotropic hormones, sex hormone syn-
thesis and metabolism and their receptors; and those encoding for
cytokines, bone biomarkers and proteins responsible for hereditary
bone disorders (i.e. low-density LRP5 and LRP6). These genes
should be considered in the choice for segregation analyses of this
multigenic disorder (Carbonell Sala et al., 2005).
Osteoporosis is inherited as a Mendelian monogenic disorder only
in rare bone diseases, although the common form of osteoporosis is
multifactorial, arising from the interaction of polymorphic alleles with
environmental and lifestyle factors interactions.
Lifestyle and dietary fracture
prevention
Osteoporosis, dietary insufﬁciency, inactivity, senile sarcopenia and
falls are all risk factors for fractures which may be modiﬁed by
changes in lifestyle. Osteoporosis is a growing concern in a society
that is characterized by a rapidly growing proportion of post-
reproductive individuals. It affects both men and women of advanced
age, although women four times more than men: one in three women
over the age of 50 will suffer an osteoporotic fracture as compared
with 1 in 12 men (Hannan et al., 2000). Changing lifestyle habits con-
tribute to the dietary and activity risks. The less active, more sedentary
lifestyle of young people today has not only caused the present obesity
epidemic, but it also will negatively impact future peak bone mass and
decrease future bone reserve capacity. Diminished peak bone mass,
together with the relative and absolute increase of elderly people in
society, will lead to a rapid increase in future osteoporotic fracture
case incidence. Currently, 50% of patients who have sustained a hip
fracture are no longer able to lead an independent life and 25% die
within 1 year.
Osteoporosis, sedentary life, falls and fractures are interrelated and
it is difﬁcult to identify individual contributing lifestyle risk factors within
this evolutionary-social disease conglomerate. Non-modiﬁable risk
factors cannot be changed, but prevention programs can be based
Figure 5 Relationship of 10 years fracture probability with age in
women with comparable osteoporosis (BMD ¼ 23SD) (Sweden)
(Kanis et al., 2001).
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on the modiﬁable risk factors such as exercise, weight, diet and
smoking (Law and Hackshaw, 1997).
Activity
An increased adolescent active lifestyle has been associated with
increased BMD later in life. Past and current participation in active
exercise programs both contribute to a higher post-menopausal
BMD (Kemmler et al., 2004). Conversely a sedentary adolescence
and sedentary lifestyles are risk factors for osteoporosis. In contrast,
among post-menopausal women, if exercise leads to a low body
mass index, this is associated with low BMD and more rapid bone
loss, and a consequent higher risk of developing osteoporosis
(Forsmo et al., 2009).
Exercise reduces the risk of falling, increases BMD and decreases
fracture risk (Kelley et al., 2001). General fall prevention activities
and/or individually tailored fall prevention interventions signiﬁcantly
reduced falls from 2.54 to 2.09 falls per patient per year (Neyens
et al., 2009). Balance and gait training, appropriate use of walking
devices, low-impact weight bearing exercises, muscular endurance
training and high-intensity strength training maintain BMD both in
elderly men and women. Regular walking promotes bone health
(Schmitt et al., 2009). Although increased physical activity may
improve osteoporosis and reduce the likelihood of falls, an impact
on fracture prevention has not yet been shown.
Diet
High lifetime dietary dairy product intake has been associated with
decreased osteoporosis risk later in life, although many of the
reports on diet and osteoporosis risk are not high quality and do
not reach ﬁrm conclusions. Nevertheless, healthy eating habits
usually maintain an adequate calcium balance and are as effective as
pharmacological agents.
In contrast to calcium, vitamin D may be insufﬁcient in otherwise
adequate diets. In a meta-analysis of trials with a dose of more than
700 IU/day the pooled relative risk was 0.80 (95% CI 0.72–0.89,
33 265 subjects, 9 trials) for non-vertebral fractures and 0.82 (95%
CI 0.69–0.97, 31 872 subjects, 5 trials) for hip fractures. Non-
vertebral fracture rates were reduced in both community (29%
fewer) and institutional (15% fewer) settings and the vitamin D
effect was independent of calcium supplementation (Bischoff-Ferrari
et al., 2005).
The relationship between other dietary factors and osteoporosis is
still unresolved. Soy-rich foods, natural progesterone, carbonated
drinks, caffeine-containing beverages have not been tested rigorously
enough to allow for ﬁrm clinical conclusions.
Smoking and alcohol
Smoking and excessive alcohol reﬂect an unhealthy lifestyle and as
such are associated with an increased fracture risk. A direct effect,
however, especially for alcohol intake, remains to be established.
The BMD in post-menopausal smokers is 2% lower than average
with each decade passed since the menopause. Stopping smoking
decreases the risk of fractures, although a signiﬁcant decrease is only
noted 10 years after cessation.
Management of osteoporosis
The aim of any intervention in osteoporosis is the prevention of frac-
tures in patients who have not yet fractured or prevention of disease
progression in patients who have already sustained a fragility fracture.
Management of osteoporotic patients involves general measures, non-
pharmacological interventions and pharmacological interventions.
General measures include correction of deﬁciencies/insufﬁciencies
in vitamin D (Bischoff-Ferrari et al., 2005; Boonen et al., 2007), and
ensuring a calcium intake of about 1200 mg per day and a protein
intake of 1.2 g/kg body weight (Kanis et al., 2008a). This should be
the ﬁrst step in the management of a patient with osteoporosis. Non-
pharmacological interventions mainly aim at reducing the frequency or
impact of falls for example, with the use of hip protectors in residents
of nursing homes at high risk for falling. Although fall prevention pro-
grams have been shown to reduce the number of falls (Neyens et al.,
2009), multifactorial fall prevention programs in primary care, commu-
nity or emergency care settings have not been consistently effective in
reducing the number of fallers or fall-related injuries (Gates et al.,
2008).
Pharmacological interventions aim at correcting the imbalance
between bone resorption and bone formation by either inhibiting
bone resorption or stimulating bone formation. Most available inter-
ventions are inhibitors of bone resorption and turnover. They
include bisphosphonates, calcitonin, estrogens, SERMs. RCTs show
that treatment improves BMD and reduces relative risk of fracture
by about 50% for vertebral, 20–25% for non-vertebral and 40% for
hip fractures (Cauley et al., 2003; Black et al., 2007; Wells et al.,
2008a, b; Cranney et al., 2009; Eastell et al., 2009), tibolone and deno-
sumab (Cummings et al., 2008, 2009). Owing to the low frequency of
the event the reduction of absolute risk is much lower and varies
depending on the baseline risk of studied patients e.g. between 1.7
and 11.1% for vertebral fractures with bisphosphonate treatment
(MacLean et al., 2008). In general, all available interventions reduce
the risk of vertebral fractures which is a prerequisite for their regulat-
ory approval. However, not all of them reduce the risk of non-
vertebral fractures and only alendronate, risedronate, zoledronate,
estrogens and denosumab have been shown to reduce the risk of
hip fractures (Table IV). The only available stimulators of bone for-
mation are PTH peptides, such as PTH 1–34 and PTH 1–84 that
prevent vertebral, for both, and non-vertebral fractures for the
former (MacLean et al., 2008). Finally, there are also compounds
whose action on bone remodeling has not yet been fully elucidated,
such as strontium ranelate (O’Donnell et al., 2006; Seeman et al.,
2006b). Strontium ranelate was effective in three trials among
women with existing fractures, with a 37% reduction in vertebral frac-
tures and a 14% reduction in non-vertebral fractures (O’Donnell et al.,
2006). In a separate analysis of women aged 80 years or more there
were reductions in vertebral and non-vertebral fractures after treat-
ment with strontium ranelate for 3 years (Seeman et al. 2006b).
The frequency and route of administration vary widely depending on
the speciﬁc pharmacological properties of each compound. Their efﬁ-
cacy is also highly dependent on adherence, which may be low with
antiosteoporosis treatments.
There have been no head-to-head trials with fractures outcomes. In
addition, fracture risk differs widely among patients included in differ-
ent clinical trials precluding comparisons of the relative efﬁcacies of
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different agents. For treatment decisions, apart from efﬁcacy, other
factors need to be carefully considered. These include the safety
and tolerability of each individual agent, the convenience of adminis-
tration and patient preferences for ensuring long-term adherence
and the cost of the intervention. The hormone therapy with estro-
gen–progestogen increase rates of thromboembolism and estrogen
and tibolone increase stroke rates (Rossouw et al., 2007; Cummings
et al., 2008; MacLean et al., 2008). The most common adverse
events with bisphosphonates are upper gastrointestinal complaints
(Solomon et al., 2009). Oesophageal cancer is rare (1 in 20 000)
but adverse event reporting has identiﬁed 23 cases associated with
use of alendronate and other bisphosphonates (Wysowski, 2009).
Osteonecrosis of the jaw (,1 per 100 000) also has been associated
with bisphosphonate use in observational studies (Solomon et al.,
2009). Such a low incidence is found in bisphophonate treatment
for osteoporosis. It may be far higher in the treatment of bone metas-
tases (Rizzoli et al., 2008). In the denosumab trial, ﬂatulence and
eczema were more common, but serious adverse events were not
more common with denosumab compared with placebo (Cummings
et al., 2009).
PTH use is associated with an increased incidence of nausea and
headache (Neer et al., 2001) while dizziness, nausea and leg cramps
are more reported by teriparatide users (Body et al., 2002).
Why treatment of osteoporosis
does not guarantee fracture
protection
In 1994 the WHO deﬁned osteoporosis as BMD below a T-score of
22.5 SD and osteopenia as a t-score in the range of 21 SD to 22.5
SD. Osteopenia is not a disease in its own right but the term usefully
describes the proportion of the population having bone loss that is not
so severe as in those with osteoporosis. Osteoporosis is of clinical
importance primarily because it is associated with low-trauma frac-
tures; the clinical emphasis is on fracture and fracture risk rather
than BMD.
Because drug licensing regulatory requirements require fracture as
the key clinical outcome of osteoporosis trials, many large clinical
trials with fracture outcomes have been reported. In these trials,
some bone active agents which have prevented bone loss have not
reduced fractures at all relevant sites. Thus the hope that treatment
of osteoporosis or osteopenia might guarantee protection from frac-
ture is not realistic.
Osteopenia
Although osteoporosis is the more severe condition of reduced BMD
it is still relevant to consider the milder state, osteopenia, for two
reasons. First, even though the risk of fracture will be lower in
people with osteopenia than osteoporosis, the osteopenia segment
of the population is much larger than the osteoporosis segment.
Thus, although their average fracture risk is lower than with osteo-
porosis, those with osteopenia make a greater contribution to the
total number of fractures. Second, the fracture risk associated with
a particular level of reduced BMD rises with age, so that an older
woman with osteopenia may have a higher absolute risk of fracture
than a younger woman with osteoporosis (Fig. 5) (Kanis et al.,
2002). The issues to address in the prevention of fracture include
not only the efﬁcacy of therapies, but also the multiple risk factors
for fracture (risk of falling and bone strength), the persistence of thera-
peutic effect, the need for intervention thresholds and the need for a
realistic health care policy framework in which the therapeutic strategy
might be applied.
Role of risk factors
The four most important risk factors for bone fractures are female
sex, older age, lower BMD and the existence of a previous low-trauma
fracture. Other risk factors, independent of their effect on BMD,
include a family history of hip fracture, rheumatoid arthritis, systemic
glucocorticoid use, excessive alcohol intake and untreated premature
menopause. The synthesis of these analyses has now been published
by WHO (Kanis et al., 2007). For females, for any given BMD, fracture
risk increases steeply with each decade of age beyond 50 years (Fig. 5).
The risk is further modulated by the presence of one of more inde-
pendent risk factors. These have been synthesized in the algorithm
underlying the web-based FRAX instrument for individualized fracture
risk assessment (www.shef.ac.uk/FRAX). Authors using FRAXTM
report that the use of the model compared with BMD alone may
improve identiﬁcation of patients at increased fracture risk (Lippuner
et al., 2010; Nanes and Kallen, 2009). Thus although BMD deﬁnes
osteopenia and osteoporosis, additional risk factors are needed for
a more accurate prediction of fracture risk.
Prevention failures
Nearly all of the treatments for osteoporosis act by reducing bone
turnover rates and the improved bone density should lower fracture
risk. Since bone strength is just one factor, however, fractures can
still occur even in treated women if the sample is sufﬁciently large
and observed over a sufﬁciently long period.
........................................................................................
Table IV Protective effect of major pharmacological
interventions on fracture risk in post-menopausal
women with osteoporosis (Compston et al., 2009).
Vertebral
fracture
Non-vertebral
fracture
Hip
fracture
HT* + + +
Raloxifene + 2 2
Alendronate + + +
Ibandronate + 2 2
Risedronate + + +
Zoledronate + + +
Strontium
ranelate
+ + 2
Teriparatide + + 2
PTH (1-84) + 2 2
+, evidence from RCTs and/or meta-analyses.
2, no evidence from existing RCTs or efﬁcacy only demonstrated on post hoc subgroup
analysis.
*, in women not selected on the base of osteoporosis or prevalent fracture.
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A useful example is the WHI study which involved more than
16 000 women age 50–79 years followed for more than 5 years
after random allocation to combined estrogen/progestogen (E + P
HT) or placebo. Unlike most osteoporosis studies the WHI popu-
lation was not selected for low BMD and may be generally represen-
tative of the post-menopausal population. The study showed that
around 5 years of effective therapy reduced but did not abolish frac-
tures (Cauley et al., 2003) and the results with other agents such as
the bisphosphonates are similar.
Duration of effects
Although osteoporosis is a lifelong disease, most trials of effectiveness
lasted ,5 years and few guidelines advocate treatment for longer than
5 years. In an extension of one 3 year trial, bone density continued to
increase with 10 mg of alendronate daily for up to 10 years (Bone
et al., 2004).
The duration of beneﬁt after stopping therapy remains a matter of
ongoing debate. Women who had taken alendronate for 5 years in a
previous trial were randomly allocated to continue or discontinue for a
further 5 years and non-vertebral fractures occurred in 19% of those
continuing and 18% of those who discontinued alendronate (Black
et al., 2006). With respect to HT, it has been controversial whether
the fracture reduction effect remains after discontinuation (Bagger
et al., 2004; Banks et al., 2004; Yates et al., 2004). In the WHI
study, the signiﬁcant hip fracture reduction during the trial was lost
during the 3 years after the trial (Heiss et al., 2008).
Cost-effectiveness
Cost-effectiveness modeling can inﬂuence whether treatment is
restricted to those with osteoporosis or extended to those who
have osteopenia. On the basis of cost-effectiveness, the UK National
Institute for Healthcare and Clinical Excellence (NICE) Technology
Appraisal on the Prevention of Fractures does not include women
with osteopenia or younger women unless they have had a low-
trauma fracture (NICE Technology appraisal, 2008a, b). In contrast,
the National Osteoporosis Guideline Group (NOGG) (2008) takes
age into account and includes the oldest women with osteopenia
because their absolute fracture risk exceeds that of younger women
with osteoporosis (Compston et al., 2009).
In conclusion, treatment recommendations are no longer based pri-
marily on BMD. As a result, those women with osteopenia who have
relatively high fracture risk because of additional factors such as age,
are also eligible for treatment. Although the large treatment trials
demonstrate clear reduction of fracture risk, none of the treatment
options can guarantee fracture prevention.
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Appendix
A meeting was organized by ESHRE (30–31 August 2009) to discuss
the above subjects. The contributors included: David H. Barlow
(Executive Dean of Medicine, Professor of Reproductive Medicine
University of Glasgow, UK), Philippe Bouchard (Hospital St Antoine
APHP, Endocrinology Unit, Paris, France), Maria Luisa Brandi (Depart-
ment of Internal Medicine, University of Florence, Italy), J.L.H. Evers
(Dept. Obstet. Gynecol., Academic Hospital Maastricht, The
Netherlands), A. Glasier (Family Planning and WW Services, Edin-
burgh, UK), Eva Negri (Istituto di Ricerche Farmacologiche ‘Mario
Negri’, Milano, Italy), Socrates E. Papapoulos (Department of Endo-
crinology and Metabolic Diseases, Leiden University Medical Center,
Leiden, The Netherlands), Stuart H. Ralston (Head of the School of
Molecular and Clinical Medicine and ARC Professor of Rheumatology
Molecular Medicine Centre, Western General Hospital, Edinburgh,
UK), Rene´ Rizzoli (Division of Bone Diseases, Department of Rehabi-
litation and Geriatrics, Faculty of Medicine, Geneva, Switzerland). The
discussants included: D.T. Baird (Centre for Reproductive Biology,
University of Edinburgh, UK), J. Collins (McMaster University, Hamil-
ton, Canada), G. Benagiano (Dipartimento di Scienze Ginecologiche,
Universita` di Roma, Italy), P.G. Crosignani (Fondazione IRCCS Ca’
Granda Ospedale Maggiore Policlinico, Milano, Italy), C. La Vecchia
(Istituto Mario Negri, Milano, Italy) and A. Volpe (Dipartimento Inte-
grato Materno Infantile, Universita` di Modena, Italy. The report was
prepared by J. Collins and P.G. Crosignani.
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